GUIDELINES EQUALITY IMPACT ASSESSMENT FORM: SCOPING

Guideline title: Type 2 diabetes: management of type 2 diabetes in adults

1. Have relevant equality issues been identified during scoping?

This guideline will consider adults with Type 2 Diabetes in all NHS care settings irrespective of gender, ethnicity, disability, religion or beliefs, sexual orientation and gender identity or socio-economic status.

Four specific patient subgroups for whom the management of type 2 diabetes may vary have been listed in scope for the guideline. However, it is recognised that management of type 2 diabetes may be variable in other patient subgroups.

The four specific patient subgroups listed within the scope are:

- People aged 60 years and above
- People with renal impairment
- People in specific ethnic groups
- People in specific cardiovascular risk groups

We will let the content of the included evidence within the guideline and the decisions of the guideline development group inform us as to where specific subgroup recommendations may be appropriate.

The update of the Type 2 Diabetes guideline will be substantial and bring likely benefit to all equality characteristic groups. It will include:

- NICE clinical guideline 66
- Type 2 diabetes-newer agents (NICE clinical guideline 87)

and will also incorporate:

- Diabetes- (type 2): Liraglutide (NICE technology appraisal guidance 203, 2010)
- Diabetes - type 2 exenatide (prolonged release) (NICE technology appraisal 248, 2012)

Remaining aware of how the update will impact on those from different socio-economic backgrounds, disability groups, older people and ethnic backgrounds (such as the South Asian community) will be particularly important in the development of this guideline, as it is these groups who are affected most by type 2 diabetes.

How we present and make the final guideline product accessible to people is an important issue too, which will require continued thought and consideration.
2. If there are exclusions listed in the scope (for example, populations, treatments or settings) are these justified?

The update of the Type 2 Diabetes guideline will not look at type 2 diabetes in those younger than 18 years and pregnant women with type 2 diabetes. However, clinical guidelines which cover gestational diabetes and type 1 and 2 diabetes in those younger than 18 years are being covered by other guideline developing centres.
3. Have relevant bodies and stakeholders been consulted?

A stakeholder workshop was held on 28 May 2012. Post-workshop stakeholder comments on the draft scope and the guideline development group membership list have been considered and incorporated.

Stakeholders were invited to comment during the scope consultation (4th July – 29th August 2012) and subsequently their comments have been considered for inclusion. The stakeholder comments and the scope for this guideline have been reviewed in conjunction with the further 3 diabetes guideline which are currently in scoping to ensure consistency between all of the diabetes guidelines.